Product Description
Alprostadil is a medication used in the management and treatment of erectile dysfunction in males and for temporary patency of ductus arteriosus in newborns with congenital heart diseases before surgical intervention. It is in the prostaglandin analog class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK542217/)
Mechanisms of Action: EP1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arteriosclerosis Obliterans|Optic Neuropathy, Ischemic
Phase 1: Angina Pectoris|Atherosclerosis|Chronic Pain|Ductus Arteriosus, Patent|Heart Failure, Chronic|Microvascular Angina|Myocardial Infarction|Retinal Vein Occlusion|Thrombosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-004982-28 |
PG-NAION | P2 |
Active, not recruiting |
Optic Neuropathy, Ischemic |
2020-05-18 |
2022-03-13 |
Treatments |
|
CTR20132242 |
CTR20132242 | P1 |
Recruiting |
Ductus Arteriosus, Patent|Thrombosis|Atherosclerosis|Heart Failure, Chronic|Retinal Vein Occlusion|Myocardial Infarction|Microvascular Angina|Angina Pectoris|Chronic Pain |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20160579 |
CTR20160579 | P2 |
Recruiting |
Arteriosclerosis Obliterans |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20191908 |
CTR20191908 | P2 |
Recruiting |
Arteriosclerosis Obliterans |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20180050 |
CTR20180050 | P2 |
Recruiting |
Arteriosclerosis Obliterans |
None |
2025-04-29 |